Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CSBR Stock Forecast 2026-2027
$5.81
Current Price
$84.24M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CSBR Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CSBR Price Momentum
+0.9%
1 Week Change
+1.6%
1 Month Change
-34.1%
1 Year Change
-15.9%
Year-to-Date Change
-39.7%
From 52W High of $9.63
+5.6%
From 52W Low of $5.50
📊 TOP ANALYST CALLS
Did CSBR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Champions Oncology is one of their latest high-conviction picks.
Latest CSBR Stock Price Targets & Analyst Predictions
CSBR has shown a year-to-date change of -15.9% and a 1-year change of -34.1%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CSBR. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CSBR Analyst Ratings
1
Buy
0
Hold
0
Sell
CSBR Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $5.81
Latest CSBR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CSBR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2025 | Craig-Hallum | Matt Hewitt | Buy | Maintains | $12.00 |
| Dec 12, 2024 | Craig-Hallum | Buy | Maintains | $N/A | |
| Sep 12, 2024 | Craig-Hallum | Buy | Upgrade | $N/A | |
| Mar 13, 2024 | Craig-Hallum | Hold | Downgrade | $N/A | |
| Sep 22, 2023 | Roth MKM | Buy | Maintains | $N/A | |
| Mar 15, 2021 | Roth Capital | Buy | Maintains | $N/A | |
| Nov 18, 2019 | Benchmark | Speculative Buy | Initiates | $N/A | |
| Sep 20, 2019 | Roth Capital | Buy | Initiates | $N/A | |
| Jul 24, 2019 | Janney Capital | Neutral | Downgrade | $N/A | |
| Jul 24, 2019 | Janney Montgomery Scott | Neutral | Downgrade | $N/A | |
| Jul 17, 2018 | Craig-Hallum | Buy | Initiates | $N/A | |
| May 15, 2018 | Dawson James | Buy | Initiates | $N/A |
Champions Oncology, Inc. (CSBR) Competitors
The following stocks are similar to Champions Oncology based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Champions Oncology, Inc. (CSBR) Financial Data
Champions Oncology, Inc. has a market capitalization of $84.24M with a P/E ratio of 35.9x. The company generates $57.95M in trailing twelve-month revenue with a -4.0% profit margin.
Revenue growth is -2.8% quarter-over-quarter, while maintaining an operating margin of -1.1% and return on equity of -47.6%.
Valuation Metrics
Market Cap
$84.24M
Enterprise Value
$77.96M
P/E Ratio
35.9x
PEG Ratio
-0.3x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
-2.8%
Gross Margin
+46.7%
Operating Margin
-1.1%
Net Margin
-4.0%
EPS Growth
-2.8%
Financial Health
Cash/Price Ratio
+8.8%
Current Ratio
1.0x
Debt/Equity
114.2x
ROE
-47.6%
ROA
-4.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Champions Oncology, Inc. (CSBR) Business Model
About Champions Oncology, Inc.
What They Do
Biotechnology company focused on oncology drug discovery.
Business Model
Champions Oncology generates revenue by providing advanced research models and technologies, specifically through their TumorGraft Technology. This service enables pharmaceutical companies and research institutions to test cancer therapies using patient-derived tumor cells, offering predictive insights that enhance drug development and clinical trial design.
Additional Information
The company's innovations support precision medicine and are essential for understanding treatment responses in various cancer types. Champions Oncology is positioned as a key partner in global cancer research initiatives, contributing to the advancement of targeted therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
213
CEO
Mr. Robert Brainin
Country
United States
IPO Year
2007
Website
www.championsoncology.comChampions Oncology, Inc. (CSBR) Latest News & Analysis
Latest News
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
3 months ago
Quick Summary
Champions Oncology, Inc. (Nasdaq:CSBR) will present data from eight studies at the AACR Annual Meeting, focusing on oncology drug development and translational risk reduction.
Why It Matters
Champions Oncology's new data presentation at AACR could enhance its credibility in oncology research, potentially attracting investment and boosting stock performance if positive outcomes are reported.
Source: Accesswire
Market Sentiment:
Neutral
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
3 months ago
Quick Summary
Champions Oncology, Inc. (Nasdaq: CSBR) appointed Dr. Brian Alexander to its Board of Directors, emphasizing its commitment to data-driven oncology research and development.
Why It Matters
Dr. Alexander's appointment signals Champions Oncology's commitment to enhancing oncology research through data, potentially boosting innovation and market competitiveness, affecting stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Champions Oncology, Inc. (CSBR) held its Q3 2026 earnings call, discussing financial results and business updates. Details on revenue, expenses, and strategic plans were provided.
Why It Matters
Champions Oncology's Q3 2026 earnings provide insights into financial performance, growth prospects, and market trends, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Champions Oncology Reports Revenue of $16.6 Million
3 months ago
Quick Summary
Champions Oncology, Inc. reported Q3 fiscal 2026 revenue of $16.6M, a 32% increase in study service revenue year-over-year, with positive adjusted EBITDA of $574,000.
Why It Matters
Champions Oncology shows strong revenue growth and a positive adjusted EBITDA, indicating operational efficiency and potential for future profitability, which boosts investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026
4 months ago
Quick Summary
Champions Oncology, Inc. (CSBR) will report Q3 financial results on March 12, 2026, after market close, followed by a conference call at 4:30 PM.
Why It Matters
Champions Oncology's upcoming financial report and conference call may influence stock performance and investor sentiment, reflecting the company's operational health and market position.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Champions Oncology, Inc. (CSBR) held its Q2 2026 earnings call, discussing financial performance and strategic developments. Investors can access the full transcript for detailed insights.
Why It Matters
The Q2 2026 earnings call provides insights into Champions Oncology's financial performance, growth potential, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About CSBR Stock
What is Champions Oncology, Inc.'s (CSBR) stock forecast for 2027?
Analyst forecasts for Champions Oncology, Inc. (CSBR) are not currently available. The stock is trading at $5.81.
Is CSBR stock a good investment in 2027?
According to current analyst ratings, CSBR has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CSBR stock?
Price predictions from Wall Street analysts for CSBR are not currently available. The stock is trading at $5.81.
What is Champions Oncology, Inc.'s business model?
Champions Oncology generates revenue by providing advanced research models and technologies, specifically through their TumorGraft Technology. This service enables pharmaceutical companies and research institutions to test cancer therapies using patient-derived tumor cells, offering predictive insights that enhance drug development and clinical trial design.
What is the highest forecasted price for CSBR Champions Oncology, Inc.?
Price targets from Wall Street analysts for CSBR are not currently available. The stock is trading at $5.81.
What is the lowest forecasted price for CSBR Champions Oncology, Inc.?
Price targets from Wall Street analysts for CSBR are not currently available. The stock is trading at $5.81.
What is the overall CSBR consensus from analysts for Champions Oncology, Inc.?
The overall analyst consensus for CSBR is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are CSBR stock price projections?
Stock price projections, including those for Champions Oncology, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 10, 2026 2:31 AM UTC